Latest QIAGEN N.V. Stories
VENLO, The Netherlands, January 16, 2015 /PRNewswire/ -- QIAGEN N.V.
HILDEN, Germany, January 12, 2015 /PRNewswire/ -- - QIAGEN's circulating tumor DNA test is now CE-IVD marked to assess EGFR mutation status in
HILDEN, Germany and GERMANTOWN, Maryland, January 8, 2015 /PRNewswire/ -- - Ongoing growth with 250 new QIAsymphony placements in 2014 - Five FDA
HILDEN, Germany and GERMANTOWN, Maryland, December 4, 2014 /PRNewswire/ -- - New molecular diagnostic test detects but does not differentiate all
HILDEN, Germany, and MANCHESTER, England, November 11, 2014 /PRNewswire/ -- - Master collaboration agreement is a framework for developing and
VENLO, The Netherlands, October 29, 2014 /PRNewswire/ -- - Achieved Q3 2014 targets: Adjusted net sales of $336.8 million (+4% CER); adjusted operating
HILDEN, Germany and TOKYO, October 28, 2014 /PRNewswire/ -- - First two programs aim to create tests to aid in cancer treatment with Astellas compounds
HILDEN, Germany and BARCELONA, Spain, October 28, 2014 /PRNewswire/ -- - New WHO guidelines launched for prevention include screening and treating
SAN DIEGO and HILDEN, Germany, October 17, 2014 /PRNewswire/ -- - Translational research in cancer and other diseases will benefit from new capabilities
VENLO, The Netherlands, October 10, 2014 /PRNewswire/ -- QIAGEN N.V.